Abstract
Serotonin (5-HT) receptors are part of the G protein-coupled and ligand-gated ion channel families. 5-HT exerts its diverse actions by binding to cell surface receptors which can be classified into seven distinct families (5-HT1 to 5- HT7) according to their structural diversity and mode of action. Some of the 5-HT families are comprised of multiple receptors which share similar structural and mechanistic properties but display very different operational profiles. Evidence continues to mount in support of the important roles of the 5-HT receptors in various neuropsychiatric disorders such as anxiety, depression, schizophrenia, migraine and drug addiction. The 5-HT receptors may also play an important role in obesity, aggression, sexual behaviour and cardiovascular disorders. A number of selective/non-selective 5-HT agonist and antagonist ligands (drugs) have been developed to challenge many of these disease states.
Keywords: 5-Hydroxytryptamine, serotonin, central nervous system (CNS), anti-migraine drugs, G-proteins, 5-HT receptor family
Current Pharmaceutical Design
Title: 5-Hydroxytryptamine (5-HT) Receptor Ligands
Volume: 13 Issue: 25
Author(s): Sean L Kitson
Affiliation:
Keywords: 5-Hydroxytryptamine, serotonin, central nervous system (CNS), anti-migraine drugs, G-proteins, 5-HT receptor family
Abstract: Serotonin (5-HT) receptors are part of the G protein-coupled and ligand-gated ion channel families. 5-HT exerts its diverse actions by binding to cell surface receptors which can be classified into seven distinct families (5-HT1 to 5- HT7) according to their structural diversity and mode of action. Some of the 5-HT families are comprised of multiple receptors which share similar structural and mechanistic properties but display very different operational profiles. Evidence continues to mount in support of the important roles of the 5-HT receptors in various neuropsychiatric disorders such as anxiety, depression, schizophrenia, migraine and drug addiction. The 5-HT receptors may also play an important role in obesity, aggression, sexual behaviour and cardiovascular disorders. A number of selective/non-selective 5-HT agonist and antagonist ligands (drugs) have been developed to challenge many of these disease states.
Export Options
About this article
Cite this article as:
Kitson L Sean, 5-Hydroxytryptamine (5-HT) Receptor Ligands, Current Pharmaceutical Design 2007; 13 (25) . https://dx.doi.org/10.2174/138161207781663000
DOI https://dx.doi.org/10.2174/138161207781663000 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Suppression of Glial HO-1 Activitiy as a Potential Neurotherapeutic Intervention in AD
Current Alzheimer Research Taking Down the Unindicted Co-Conspirators of Amyloid β-Peptidemediated Neuronal Death: Shared Gene Regulation of BACE1 and APP Genes Interacting with CREB, Fe65 and YY1 Transcription Factors
Current Alzheimer Research Transcription Factors as Therapeutic Targets in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Prevalence of Anxiety, Depression, Sleep Disturbance, Fibromyalgia, Obesity, and Gastroesophageal Disease in Patients with Rheumatic Diseases
Current Rheumatology Reviews Urinary Steroids Measured by Modern Separation Techniques and Applied as Biomarkers in Stress Studies
Current Pharmaceutical Analysis Commentary: Death Associated Protein Kinase 1: A Perp in Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Thyroid Hormone Treatment for Differentiated Thyroid Carcinoma: What Drug, How Long, What Dose?
Current Cancer Therapy Reviews Synaptic Transmission at Functionally Identified Synapses in the Enteric Nervous System: Roles for Both Ionotropic and Metabotropic Receptors
Current Neuropharmacology Cell-Based Therapy to Promote Angiogenesis in the Brain Following Ischemic Damage
Current Vascular Pharmacology KDS2010: A Potent Highly Selective and Reversible MAO-B Inhibitor for Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Dev elopment (Part C))
Current Pharmaceutical Design Quinolinic Carboxylic Acid Derivatives as Potential Multi-target Compounds for Neurodegeneration: Monoamine Oxidase and Cholinesterase Inhibition
Medicinal Chemistry Editorial [Hot Topic: Frontiers of Metabolomics – Going from Bench to Bedside (Guest Editor: Anders Nordstrom)]
Current Pharmaceutical Biotechnology Cortical Consequences of HIV-1 Tat Exposure in Rats are Enhanced by Chronic Cocaine
Current HIV Research High-Throughput Screening of Neuronal Cl- Channels: Why and How?
Current Neuropharmacology Correlating Low-Similarity Peptide Sequences and Allergenic Epitopes
Current Pharmaceutical Design TARDBP Ala382Thr Mutation in Multiple Sclerosis: A Possible Role in Brain Atrophy
Current Medical Imaging Reducing Gabaergic Inhibition Restores Cognitive Functions in a Mouse Model of Down Syndrome
CNS & Neurological Disorders - Drug Targets Vitamin D Analogs: Mechanism of Action and Therapeutic Applications
Current Medicinal Chemistry HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET
Current Drug Targets